Centene's Q3 Beat Supports Continued Earnings Recovery, RBC Says

MT Newswires Live01:46

Centene's (CNC) Q3 beat supports its ongoing earnings recovery, RBC Capital Markets said in a note emailed Friday.

In late October, the company reported Q3 adjusted earnings of $0.58 per diluted share. Analysts polled by FactSet expected $0.10. Revenue for the quarter was $50.65 billion. Analysts expected $47.12 billion.

The analysts said the company's Medicare Advantage business reached breakeven a year ahead of plan, while its prescription drug plan business delivering mid-to-high 3% margins.

Looking ahead to 2027, management expects about $0.50 in 2026 earnings items that will not recur, providing a starting point of roughly $4.70, the analysts said, adding that uncertainties remain around membership losses related to the One Big Beautiful Bill Act.

"Following a deeply disruptive 2025, CNC enters 2026 with clear early evidence of a multi-year earnings recovery," the analysts said.

RBC raised its price target on Centene to $73 from $71 while keeping its sector perform rating.

Price: 65.00, Change: -0.58, Percent Change: -0.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment